results

RINVOQ

For adults with moderate to severe rheumatoid arthritis (RA) in whom TNF blockers did not work well.

Fast relief that can last

In a clinical study, RINVOQ helped relieve RA
joint pain, swelling, and stiffness symptoms, for some as   as 1 week

The majority of people taking RINVOQ had significantly improved symptoms at 12 weeks

Relief even at 5 years

Many people still taking RINVOQ continued to see improvement of RA symptoms even at  

In this less rigorous part of the study, patients and physicians were aware of RINVOQ treatment, which may have influenced the results at 5 years (260 weeks).

*20% improvement in RA symptoms when used with csDMARDs. A doctor could adjust supportive RA medicines as needed starting at week 24.

Individual results may vary.

In clinical studies, RINVOQ is also proven to help:

Stop further irreversible joint damage to prevent more progression

Make it easier to do everyday things so you can get back
to what you enjoy, like gardening and going on walks

Significantly reduce RA fatigue to help you get through your day

RINVOQ'S LEGACY

RINVOQ has been studied for over 11 years in clinical trials
and has been prescribed to more than 100,000 people for RA in the US since 2019

Select Important Safety Information

RINVOQ may cause serious side effects, including:

  • Serious infections, Cancer and Immune System Problems, and Blood Clots.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Increased risk of major cardiovascular events such as heart attack, stroke, or death in people age 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.

Safety Considerations

RINVOQ may cause serious side effects, including:

  • Serious infections. RINVOQ can lower ability to fight infections. Serious infections, some fatal, occurred, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Cancer and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer.
  • Increased risk of major cardiovascular events such as heart attack, stroke, or death in people age 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Blood clots, some fatal, in veins of the legs or lungs and arteries. This occurred more often in people 50+ with at least 1 heart disease risk factor.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.
  • Tears in the stomach or intestines; changes in certain laboratory test results.

Learn more about these and the full Important Safety Information below.

Now that my symptoms are under control, I can get back into my workshop.

I’m Back in action.”

—Stacey, on RINVOQ since 2019

Have you previously or currently been prescribed a TNF blocker like HUMIRA® or ENBREL® for your moderate to severe RA?

HUMIRA® is a registered trademark of AbbVie Inc. ENBREL® (etanercept) is a registered trademark of Immunex Corporation in the US.

Understanding the possible side effects of RINVOQ

Consider the benefits and risks of taking
RINVOQ to make an informed treatment choice
with your rheumatologist.

NEXT PAGE